

## SEQUENCE LISTING

&lt;110&gt; Bayer HealthCare AG

<120> Diagnostics and Therapeutics for Diseases Associated with  
Kallikrein 12 (KLK12)

&lt;130&gt; BHC 04 01 018

&lt;160&gt; 5

&lt;170&gt; PatentIn version 3.2

&lt;210&gt; 1

&lt;211&gt; 1074

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

```

gcaggtaggt ggacggagag atagcagcga cgaggacagg ccaaacagtg acagccacgt      60
agaggatctg gcagacaaaag agacaagggtg agaaggagac tttggaagtg acccaccatg      120
gggctcagca tctttttgct cctgtgtgtt cttgggctca gccaggcagc cacaccgaag      180
attttcaatg gcactgagtg tgggcgtaac tcacagccgt ggcaggtggg gctgtttgag      240
ggcaccagcc tgcgctgcgg ggggtgcctt attgaccaca ggtgggtcct cacagcggct      300
cactgcagcg gcagcaggta ctgggtgcgc ctgggggaac acagcctcag ccagctcgac      360
tggaccgagc agatccggca cagcggcttc tctgtgacct atcccggtta cctgggagcc      420
tcgacgagcc acgagcacga cctccggctg ctgcggctgc gcctgcccgt ccgcgtaacc      480
agcagcgttc aacccctgcc cctgcccaat gactgtgcaa ccgctggcac cgagtgccac      540
gtctcaggct ggggcatcac caaccaccca cggaacccat tcccggatct gctccagtgc      600
ctcaacctct ccatcgtctc ccatgccacc tgccatggtg tgtatcccg gagaatcacg      660
agcaacatgg tgtgtgcagg cggcgtcccg gggcaggatg cctgccaggg tgattctggg      720
ggccccctgg tgtgtggggg agtccttcaa ggtctggtgt cctgggggtc tgtggggccc      780
tgtggacaag atggcatccc tggagtctac acctatattt gcaagtatgt ggactggatc      840
cggatgatca tgaggaacaa ctgacctgtt tcctccacct ccaccccac cccttaactt      900
gggtacccct ctggccctca gagcaccaat atctcctcca tcaactcccc tagctccact      960
cttgttgggc tgggaacttc ttggaacttt aactcctgcc agcccttcta agaccacga     1020
gcggggtgag agaagtgtgc aatagtctgg aataaatata aatgaaggag gggc         1074

```

&lt;210&gt; 2

&lt;211&gt; 248

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

- 2 -

Met Gly Leu Ser Ile Phe Leu Leu Leu Cys Val Leu Gly Leu Ser Gln  
 1 5 10 15  
 Ala Ala Thr Pro Lys Ile Phe Asn Gly Thr Glu Cys Gly Arg Asn Ser  
 20 25 30  
 Gln Pro Trp Gln Val Gly Leu Phe Glu Gly Thr Ser Leu Arg Cys Gly  
 35 40 45  
 Gly Val Leu Ile Asp His Arg Trp Val Leu Thr Ala Ala His Cys Ser  
 50 55 60  
 Gly Ser Arg Tyr Trp Val Arg Leu Gly Glu His Ser Leu Ser Gln Leu  
 65 70 75 80  
 Asp Trp Thr Glu Gln Ile Arg His Ser Gly Phe Ser Val Thr His Pro  
 85 90 95  
 Gly Tyr Leu Gly Ala Ser Thr Ser His Glu His Asp Leu Arg Leu Leu  
 100 105 110  
 Arg Leu Arg Leu Pro Val Arg Val Thr Ser Ser Val Gln Pro Leu Pro  
 115 120 125  
 Leu Pro Asn Asp Cys Ala Thr Ala Gly Thr Glu Cys His Val Ser Gly  
 130 135 140  
 Trp Gly Ile Thr Asn His Pro Arg Asn Pro Phe Pro Asp Leu Leu Gln  
 145 150 155 160  
 Cys Leu Asn Leu Ser Ile Val Ser His Ala Thr Cys His Gly Val Tyr  
 165 170 175  
 Pro Gly Arg Ile Thr Ser Asn Met Val Cys Ala Gly Gly Val Pro Gly  
 180 185 190  
 Gln Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Gly Gly  
 195 200 205  
 Val Leu Gln Gly Leu Val Ser Trp Gly Ser Val Gly Pro Cys Gly Gln  
 210 215 220  
 Asp Gly Ile Pro Gly Val Tyr Thr Tyr Ile Cys Lys Tyr Val Asp Trp  
 225 230 235 240  
 Ile Arg Met Ile Met Arg Asn Asn  
 245

&lt;210&gt; 3

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; forward primer

&lt;400&gt; 3

ctcttggttg cctgggaact

20

&lt;210&gt; 4

<211> 19

<212> DNA

<213> artificial sequence

<220>

<223> reverse primer

<400> 4

cgcctcgtgg gtcttagaa

19

<210> 5

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> probe

<400> 5

cttggaactt taactcctgc cagcc

25